We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Latest Industry Insights
Eliciting the Hormetic Effect:  The Importance of Plant Alkaloids for Treatment of Inflammation
Industry Insight

Eliciting the Hormetic Effect: The Importance of Plant Alkaloids for Treatment of Inflammation

Today, plant alkaloids are attracting notice as novel therapies for conditions involving inflammation, such as metabolic syndrome, autoimmune disease and even for aging, which are often characterized by chronic, low-grade over-activation of the immune system. This piece takes a closer look at the need for novel treatments and the best uses for plant alkaloids.
New Clinical Trial Explores Safety of DMT for Substance Use Disorders
Industry Insight

New Clinical Trial Explores Safety of DMT for Substance Use Disorders

Substance use disorders have a debilitating impact on the wellbeing of individuals and their families. Like many other mental health disorders, these conditions have proved stubbornly resistant to treatment. New clinical trials are exploring the safety of the psychedelic DMT for the treatment of these disorders.
How Much Psilocybin Do You Need To Rewire Your Brain?
Industry Insight

How Much Psilocybin Do You Need To Rewire Your Brain?

The therapeutic effects of the psychedelic compound psilocybin, derived from so-called “magic mushrooms” such as Psilocybe semilanceata, are now being more widely understood by medical science. New efforts are trying to tease out what would be a minimal effective dose of psilocybin, one that would have beneficial effects on the brain whilst minimizing hallucinatory experiences. Technology Networks talked to Steven Sadoff of Canadian company Sansero Life Sciences to find out more.
Cell Replacement Therapy – A Promising Treatment for Age-Related Macular Degeneration
Industry Insight

Cell Replacement Therapy – A Promising Treatment for Age-Related Macular Degeneration

Here we share a Q&A with Brian Culley, CEO of Lineage Cell Therapeutics. In this interview, Brian discusses age-related macular degeneration and retinal pigment epithelium transplant therapy.
Exploring the Challenges and Opportunities of Harvesting CTCs
Industry Insight

Exploring the Challenges and Opportunities of Harvesting CTCs

In a recent study, CTCs were harvested to investigate the causes of brain metastasis in non-small cell lung cancer patients. We spoke to Andrew Newland, CEO, ANGLE, to learn more about the study, the challenges of harvesting CTCs and how the Parsortix system overcomes some of these challenges.
A Vaccine for Alzheimer’s Disease? An Interview With AC Immune’s Prof Andrea Pfeifer
Industry Insight

A Vaccine for Alzheimer’s Disease? An Interview With AC Immune’s Prof Andrea Pfeifer

Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. 2020 has brought mixed news for AC Immune's therapeutics, including promising safety data for their anti-Alzheimer's disease vaccine candidate. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.
Making Mushrooms: How Psilocybin Is Extracted and Used in Mental Health Research
Industry Insight

Making Mushrooms: How Psilocybin Is Extracted and Used in Mental Health Research

Psilocybin’s emergence as a valuable tool for mental health research has been a huge breakthrough for the field. But how do researchers get their hands on this heavily regulated substance? Technology Networks talked to Tim Moore, CEO of Havn Life Sciences, a company that produces psychoactive compounds from plants and fungi, to find out more.
Could DMT-Assisted Therapy Help Treat Mental Health Disorders?
Industry Insight

Could DMT-Assisted Therapy Help Treat Mental Health Disorders?

The role that psychedelic therapeutics could play in tackling many intractable mental health conditions has finally been recognized by mainstream medicine. To find out more, we spoke to Carol Routledge, Chief Medical & Scientific Officer at Small Pharma.
Developing Novel Treatments for CNS Diseases
Industry Insight

Developing Novel Treatments for CNS Diseases

The discovery and development of drugs to treat diseases of the central nervous system (CNS) is particularly challenging compared to other disease areas. The blood–brain barrier restricts access to the brain, making the targeted delivery of drugs arduous, and in many cases, we are yet to have a complete understanding of the biology behind CNS disorders. In this industry insight, Brad Margus, CEO at Cerevance, tells us more about the company’s drug development pipeline and their lead candidate CVN424, which is currently being developed to treat Parkinson’s disease.
Progress in Companion Diagnostic Development for Low-Grade Glioma
Industry Insight

Progress in Companion Diagnostic Development for Low-Grade Glioma

To learn about the benefits of accelerating turnaround times for genomic testing and the importance of partnering with pharma companies to develop companion diagnostics, Technology Networks spoke with Luca Quagliata, PhD, BCMAS, global director of medical affairs for Thermo Fisher Scientific.
Advertisement